Subscribe
shutterstock_1349460611_pavel_kapysh-1-1
Pavel Kapysh / Shutterstock.com
2 August 2022AmericasStaff Writer

Pharma unit could get green light to launch IBS generic

Dispute centres on Xifaxan, used to treat irritable bowel syndrome | ‘Significant hurdle’ cleared in bringing drug to market | Bausch wins partial victory after Alvogen subsidiary failed to show that patent claims were obvious.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Bausch Health unit prevails in patent dispute
18 August 2022   New Jersey court dismissed a suit regarding an oral antibiotic | Prior art invalidated plaintiff’s four patents.
Americas
Bausch Health resolves IBS patent litigation
7 May 2020   Canada-based Bausch Health has agreed to settle its dispute with generic maker Sandoz over the latter’s attempt to release a generic version of antibiotic Xifaxan.
Americas
Senju, Bausch settle eye drop litigation against Indian generics maker
9 January 2020   Senju Pharmaceutical and Bausch Health have reached an “amicable settlement” to its patent suit against Aurobindo over generic Prolensa eye drops, court filings confirm.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Americas
Bausch Health unit prevails in patent dispute
18 August 2022   New Jersey court dismissed a suit regarding an oral antibiotic | Prior art invalidated plaintiff’s four patents.
Americas
Bausch Health resolves IBS patent litigation
7 May 2020   Canada-based Bausch Health has agreed to settle its dispute with generic maker Sandoz over the latter’s attempt to release a generic version of antibiotic Xifaxan.
Americas
Senju, Bausch settle eye drop litigation against Indian generics maker
9 January 2020   Senju Pharmaceutical and Bausch Health have reached an “amicable settlement” to its patent suit against Aurobindo over generic Prolensa eye drops, court filings confirm.

More on this story

Americas
Bausch Health unit prevails in patent dispute
18 August 2022   New Jersey court dismissed a suit regarding an oral antibiotic | Prior art invalidated plaintiff’s four patents.
Americas
Bausch Health resolves IBS patent litigation
7 May 2020   Canada-based Bausch Health has agreed to settle its dispute with generic maker Sandoz over the latter’s attempt to release a generic version of antibiotic Xifaxan.
Americas
Senju, Bausch settle eye drop litigation against Indian generics maker
9 January 2020   Senju Pharmaceutical and Bausch Health have reached an “amicable settlement” to its patent suit against Aurobindo over generic Prolensa eye drops, court filings confirm.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB